Mayoly Spindler completes the acquisition of Pharm Nature

PHARM-NATURE_Communique_presse_EN_FINAL

Mayoly Spindler completed the acquisition of Ipsen’s CHC branch

20220728_Press Release_Mayoly Spindler_Ipsen CHC closing-VSJA-Clean

Mayoly Spindler acquires Pharm Nature and strengthens its position in natural food supplements

20220630_PHARM-NATURE_Communique_presse_EN_v2.2

Mayoly Spindler announces that it has entered exclusive negotiations with IPSEN (IPN) to acquire its Consumer Healthcare branch, which includes established brands such as Smecta®, Forlax® and Tanakan®, recognized by practitioners and patients worldwide, and distributed in more than 80 countries.

This acquisition would be in line with Mayoly Spindler’s development strategy. A French, family-owned and independent pharmaceutical group, Mayoly Spindler seeks to become one of the world’s leading gastroenterology and dermocosmetics companies through this acquisition. The company has built its development around specialties that are also recognized worldwide, such as Meteospasmyl®, Probiolog® or Topicrem®, many of which are complementary to Ipsen CHC’s therapeutic solutions.

This transaction would accelerate Mayoly Spindler’s development and strengthen its long-term ambition of being a top ten European OTC drugs players as well as becoming part of the top 5 European OTC gastroenterology drugs provider over the next 10 years. With 2,200 employees across all continents, the new entity would benefit from a strong industrial footprint in France, portfolio complementarities in its therapeutic areas, unique commercial synergies and pooled investments in research and development.

“We are proud to be retained by Ipsen as the acquiror of their CHC business, and we look forward to welcoming their employees in order to build together a leading player in consumer healthcare, relying on world-renowned pharmaceutical specialties, a strong industrial footprint in France and a global presence,” said Jean-Nicolas Vernin, Chairman, and Nicolas Giraud, CEO of Mayoly Spindler.

In addition to the support of the historical banking partners, Capza and Caravelle, two French and European financial partners specialized in operations of this scale, will supply part of the funds required to complete this transaction, by acquiring a minority stake in the combined entity.

“We are particularly pleased to support this ambitious growth project in an industry we know well, and to contribute to the creation of a French champion in consumer healthcare”, commented Lorène Martel, President of Caravelle, Guillaume Basquin and Frédéric Chiche, Partners and Co-Heads of Capza Expansion.

The proposed acquisition will be subject to the consultation of employee representative bodies, as well as the finalization of the legal documentation and the customary authorizations, in accordance with the regulations in force. Mayoly Spindler expects to complete the acquisition in the third quarter of 2022.

***

Media Contacts
Florian Ridard / florian.ridard@vae-solis.com / +33 7 69 59 14 95
Alexis de Maigret / alexis.demaigret@vae-solis.com / + 33 6 13 62 38 23

***

About Mayoly Spindler
Founded in 1909, Mayoly Spindler is a French, international and independent pharmaceutical company, specialising in Gastroenterology and Dermo-cosmetics. With over 50% of its turnover generated internationally, Mayoly Spindler is continuing its development which started over 110 years ago. With their own production facilities, Mayoly Spindler is able to manage its own industrial developments. Therefore, 62% of the products it sells are made in France. Mayoly Spindler values entrepreneurship, pragmatism and accountability within a caring organisation. All Mayoly Spindler teams work together to build the future of the company and contribute to its global ambitions. Mayoly Spindler is a health entrepreneur committed to supporting patients every day in their well-being and health. To learn more, please visit: https://www.mayoly-spindler.fr/en/ or follow us on Twitter and LinkedIn.

About Ipsen CHC
Ipsen’s purpose in consumer healthcare is to bring people across the world care and comfort in their daily lives with healthcare solutions they can trust. Ipsen Consumer HealthCare develops and markets a wide range of innovative solutions – drugs, medical devices and probiotics – in four therapeutic areas: gastroenterology, cognitive disorders, pain, cough and cold. Ipsen Consumer HealthCare is present in 80 countries and employs 1,200 people.